• Skip to primary navigation
  • Skip to main content
  • Skip to footer

HepVu

HepVu

An estimated 3.5 million people in the U.S. are living with chronic Hepatitis C infection.

  • INTERACTIVE MAP
  • Location Profiles
  • Find Services
  • News & Updates
  • Events
  • Tools & Resources
Home News & Updates A Year in Review: HepVu’s 2019 Highlights

A Year in Review: HepVu’s 2019 Highlights

December 12, 2019

As 2019 draws to a close, HepVu takes a look back at this year's highlights – from our most-shared infographics to new data to insightful Q&As with viral hepatitis and opioid experts.

Our Most Popular Infographics of 2019

Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn

Data Launches

Share Facebook Twitter Pinterest LinkedIn

Hepatitis C Prevalence Estimates

HepVu launched interactive maps and updates to state profiles showing state-level estimates of people living with Hepatitis C across the U.S. from 2013 to 2016 – illustrating where communities have been hit hardest by the disease.

Learn More >>

Opioid Indicators

Three new state-level maps were launched to visualize opioid prescription rate (2017), narcotic overdose mortality rate (2013-2016), and pain reliever misuse prevalence (2015-2016), highlighting the infectious disease consequences of the opioid epidemic.

Learn More >>

Deeper Look: Opioids

Our Deeper Look: Opioids page introduced this year examines the opioid crisis as one of the greatest public health challenges facing the U.S., which has caused an unprecedented surge in drug overdose deaths and fueled the rapid rise in new Hepatitis C infections from injection drug use.

Learn More >>

New Advisory Committee Members

The AIDSVu and HepVu Advisory Committee was honored to welcome new members joining its distinguished group of national HIV and viral hepatitis experts to guide the Vu platforms’ strategic direction. Among our new members are Dr. Judith Feinberg and Michael Ninburg, two leading viral hepatitis experts.

Share Facebook Twitter Pinterest LinkedIn

Judith Feinberg, MD, Professor, Behavioral Medicine & Psychiatry, WVU School of Medicine

Dr. Feinberg is a Professor of Medicine/Infectious Diseases and a Professor of Behavioral Medicine and Psychiatry at West Virginia University. She also serves as the E.B. Flink Vice Chair of Medicine for Research. Dr. Feinberg has also long been involved in various public health aspects of HIV/AIDS, including resource allocation, policy development, the FDA approval process, and the development of harm reduction programs to prevent the spread of HIV and hepatitis due to the current opioid epidemic.

Learn More

Michael Ninburg, Executive Director, Hepatitis Education Project

Michael Ninburg is the Executive Director of the Hepatitis Education Project (HEP), a U.S.-based non-governmental organization dedicated to supporting hepatitis patients. HEP works with patients, clinicians, and policymakers and provides direct services and advocacy for some of the community’s most underserved and marginalized populations, including prisoners and people who use drugs. Michael works with global partners on issues related to hepatitis testing, treatment access, and the development of more efficient hepatitis drugs and diagnostics.

Learn More

Insights from HepVu Q&As

We continued to expand on HepVu’s series of Q&A blogs, speaking with nearly a dozen viral hepatitis and opioid experts.

Share Facebook Twitter Pinterest LinkedIn

Vu Q&A: Monica Graybeal on Ending Hep C in Washington State

Dr. Monica Graybeal, PharmD, a Hepatitis C ambulatory and community pharmacist at Yakima Valley Farm Workers Clinic, discusses Hepatitis C elimination efforts in Washington State and the need to improve access to Hepatitis C treatment for at-risk communities.

Learn More

Vu Q&A: Dr. John Ward on Global Hepatitis Elimination

Dr. John Ward, the Director of the Coalition for Global Hepatitis Elimination, discusses his work with The Coalition for Global Hepatitis Elimination and strategies the organization uses to help prevent viral hepatitis outbreaks.

Learn More

Vu Q&A: Guillermo Chacón on Hepatitis among Hispanics/Latinx

Guillermo Chacón, President of the Latino Commission on AIDS, discusses how the Commission raises awareness of the impact of viral hepatitis on the Latinx community and the need for services and programs to address health inequities and a lack of inclusivity in HIV and viral hepatitis care.

Learn More

Vu Q&A: Michelle Rose on Perinatal Hepatitis C Transmission in Kentucky

Michelle Rose, MBA, Population Health Manager for Norton Healthcare in Kentucky, explains how testing pregnant women for Hepatitis C throughout the state is helping to reduce perinatal transmission of the virus.

Learn More

Vu Q&A: The Opioid Epidemic’s Impact on Hepatitis C in the U.S.

Heather Bradley, PhD, Assistant Professor of Epidemiology at Georgia State University, and Dr. Ron Valdiserri, MPH, Professor of Epidemiology at Emory University, discuss how the opioid epidemic is fueling a rise of new Hepatitis C infections in younger Americans.

Learn More
Share Facebook Twitter LinkedIn Email

Keep Reading

April 14, 2025

What's New in Viral Hepatitis - April 2025

Read More

February 20, 2025

What's New in Viral Hepatitis - February 2025

Read More

December 11, 2024

What's New in Viral Hepatitis - December 2024

Read More

November 21, 2024

World Hepatitis Testing Week 2024 Toolkit

Read More

Sign up for HepVu updates.

Footer

AIDSVu HepVu

HepVu is presented by Emory University’s Rollins School of Public Health in partnership with Gilead Sciences, Inc.

  • About
  • FAQ
  • Data Methods
  • Datasets

Questions?
Info@HepVu.org

Media Inquiries
(202) 854-0480
Media@HepVu.org

Follow Us

  • Facebook
  • Twitter

© 2025 HepVu. All Rights Reserved.

  • Privacy Policy
  • Contact Us

Get HepVu in Your Inbox

Sign up to stay informed on new data, maps, expert Q&As, and infographics about Hepatitis C and opioids where you live.